Pirfenidone inhibits epithelial–mesenchymal transition in keloid keratinocytes

Abstract

Background: Keloids are benign fibroproliferative skin lesions that are difficult to treat and become a lifetime predicament for patients. Several treatment modalities have been put forth, but as yet no satisfactory approach to the prevention or treatment of keloids has been identified. The process of epithelial-to-mesenchymal transition (EMT) has been implicated in keloid scarring, as keloid keratinocytes display an EMT-like phenotype. This study investigated the potential of pirfenidone, an antifibrotic agent, to counteract EMT-like alterations in keloid keratinocytes, including gene expression, cell migratory and proliferative functions. Methods: Normal and keloid keratinocytes were isolated from discarded normal skin tissues and from resected keloid tissues, respectively. Cells were quiesced for 24 h without epidermal growth factor DS-Qi1MCDigital and were exposed to transforming growth factor-beta1 (TGF-β1; 10 ng/mL), with or without pirfenidone (400 μg/mL), for an additional 24 h. The effects of pirfenidone on cytotoxicity, cell migration, cell proliferation, and on expression of genes and proteins involved in EMT were assayed. Statistical significance was determined by two-way ANOVA using Sigma Plot. Results: We found that pirfenidone did not elicit any cytotoxic effect at concentrations up to 1000 μg/mL. A statistically significant dose-dependent decrease in basal cell proliferation rate was noted in both normal and keloid keratinocytes when exposed to pirfenidone at concentrations ranging from 200 to 1000 μg/mL. Pirfenidone significantly decreased basal cell migration in both normal and keloid keratinocytes, but a significant decrease in TGF-β1-induced cell migration was seen only in keloid keratinocytes. Significant inhibition of the expression of TGF-β1-induced core EMT genes, namely hyaluronan synthase 2, vimentin, cadherin-11, and wingless-type MMTV integration site family, member 5A along with fibronectin-1, was observed in both normal and keloid keratinocytes treated with pirfenidone. In addition, the protein levels of vimentin and fibronectin were significantly reduced by pirfenidone (400 μg/mL) in both normal and keloid keratinocytes. Conclusions: For the first time, this study shows the efficacy of pirfenidone in inhibiting the EMT-like phenotype in keratinocytes derived from keloids, suggesting that pirfenidone may counteract a critical contributor of keloid progression and recurrence.

Keywords

Keloids / EMT genes / Cell migration / Proliferation / Pirfenidone / Fibronectin

References

[1] van Leeuwen MC, Bulstra AE, Ket JC, Ritt MJ, van Leeuwen PA, Niessen FB. Intralesional cryotherapy for the treatment of keloid scars: evaluating effectiveness. Plast Reconstr Surg Glob Open. 2015; 3: e437.

[2] Jumper N, Paus R, Bayat A. Functional histopathology of keloid disease. Histol Histopathol. 2015; 30: 1033-57.

[3] Furtado F, Hochman B, Ferreira LM. Evaluating keloid recurrence after surgical excision with prospective longitudinal scar assessment scales. J Plast Reconstr Aesthet Surg. 2012; 65: e175-81.

[4] Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG.Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med. 2011; 17: 1-25.

[5] Poetschke J, Gauglitz GG. Current options for the treatment of pathological scarring. J Dtsch Dermatol Ges. 2016; 14: 467-77.

[6] Ogawa R.Keloid and hypertrophic scars are the result of chronic inflammation in the reticular dermis. Int J Mol Sci. 2017; 18: 606.

[7] Jiao H, Dong P, Yan L, Yang Z, Lv X, Li Q, et al. TGF-β1 induces polypyrimidine tract binding protein to alter fibroblasts proliferation and fibronectin deposition in keloid. Sci Rep. 2016; 6: 38033.

[8] Sandulache VC, Parekh A, Li-Korotky H, Dohar JE, Hebda PA. Prostaglandin E2 inhibition of keloid fibroblast migration, contraction, and transforming growth factor (TGF)-beta1-induced collagen synthesis. Wound Repair Regen. 2007; 15: 122-33.

[9] Nirodi CS, Devalaraja R, Nanney LB, Arrindell S, Russell S, Trupin J. Chemokine and chemokine receptor expression in keloid and normal fibroblasts. Wound Repair Regen. 2000; 8: 371-82.

[10] Dong X, Mao S, Wen H, Xianglin D. Upregulation of proinflammatory genes in skin lesions may be the cause of keloid formation (review). Biomed Rep. 2013; 1: 833-6.

[11] Huang C, Murphy GF, Akaishi S, Ogawa R. Keloids and hypertrophic scars: Update and future directions. Plast Reconstr Surg Glob Open. 2013; 1: e25.

[12] Hahn JM, McFarland KL, Combs KA, Supp DM. Partial epithelial-mesenchymal transition in keloid scars: regulation of keloid keratinocyte gene expression by transforming growth factor-β1. Burns Trauma. 2016; 4: 30.

[13] Yan C, Grimm WA, Garner WL, Qin L, Travis T, Neiman T, et al. Epithelial to mesenchymal transition in human skin wound healing is induced by TNF-α through bone morphogenic protein2. Am J Pathol. 2010; 176: 2247-58.

[14] Ma X, Chen J, Xu B, Long X, Qin H, Zhao RC, et al. Keloid-derived keratinocytes acquire a fibroblast-like appearance and an enhanced invasive capacity in a hypoxic microenvironment in vitro. Int J Mol Med. 2015; 35: 1246-56.

[15] Chen T, You Y, Jiang H, Wang ZZ. Epithelial-mesenchymal transition (EMT): a biological process in the development of stem cell differentiation and tumorigenesis. J Cell Physiol. 2017; 232: 3261-72.

[16] Kuwahara H, Tosa M, Egawa S, Murakami M, Mohammad G, Ogawa R. Examination of epithelial mesenchymal transition in keloid tissues and possibility of keloid therapy target. Plast Reconstr Surg Glob Open. 2016; 4: e1138.

[17] Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal 2014; 7: re8.

[18] Battula VL, Evans KW, Hollier BG, Shi Y, Marini FC, Ayyanan A, et al. Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells. 2010; 28: 1435-45.

[19] Yan L, Cao R, Wang L, Liu Y, Pan B, Yin Y, et al. Epithelial-mesenchymal transition in keloid tissues and TGF-β1-induced hair follicle outer root sheath keratinocytes. Wound Repair Regen. 2015; 23: 601-10.

[20] Finnson KW, McLean S, Di Guglielmo GM, Philip A. Dynamics of transforming growth factor beta signaling in wound healing and scarring. Adv Wound Care. 2013; 2: 195-14.

[21] Wang R, Ghahary A, Shen Q, Scott PG, Roy K, Tredget EE. Hypertrophic scar tissues and fibroblasts produce more transforming growth factor-beta1 mRNA and protein than normal skin and cells. Wound Repair Regen. 2000; 8: 128-37.

[22] Xia W, Phan TT, Lim IJ, Longaker MT, Yang GP. Complex epithelial-mesenchymal interactions modulate transforming growth factor-beta expression in keloid-derived cells. Wound Repair Regen. 2004; 12: 546-56.

[23] Lopez-de la Mora DA, Sanchez-Roque C, Montoya-Buelna M, Sanchez-Enriquez S, LucanoLanderos S, Marcias-Barragan J, et al. Role and new insights of Pirfenidone in fibrotic disease. Int J Med Sci. 2015; 12: 840-7.

[24] Shi K, Wang F, Xia J, Zuo B, Wang Z, Cao X. Pirfenidone inhibits epidural scar fibroblast proliferation and differentiation by regulating TGF-β1-induced Smad-dependent and-independent pathways. Am J Transl Res. 2019; 11: 1593-1604.

[25] Armendariz-Borunda J, Lyra-Gonzalez I, Medina-Preciado D, Gonzalez-Garcia I, Martinez-Fong D, Miranda RA, et al. A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients. Ann Plast Surg. 2012; 68: 22-8.

[26] Jin J, Togo S, Kadoya K, Tulafu M, Namba Y, Iwai M, et al. Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1. Respir Res. 2019; 10: 119.

[27] Zhou C, Liu F, Gallo P, Baratz ME, Kathju S, Satish L. Antifibrotic action of pirfenidone in Dupuytren’s disease-derived fibroblasts. BMC Musculoskelet Disord. 2016; 17: 469.

[28] Zhou C, Zeldin Y, Baratz ME, Kathju S, Satish L. Investigating the effects of pirfenidone on TGF-β1 stimulated non-SMAD signaling pathways in Dupuytren’s disease-derived fibroblasts. BMC Musculoskelet Disord. 2019; 20: 135.

[29] Saito M, Yamazaki M, Maeda T, Matsumura H, Setoguchi Y, Tsuboi R. Pirfenidone suppresses keloid fibroblast-embedded collagen gel contraction. Arch Dermatol Res. 2012; 304: 217-22.

[30] Usugi E, Ishii K, Hirokawa Y, Kanayama K, Matsuda C, Uchida K, et al. Antifibrotic agent pirfenidone suppresses proliferation of human pancreatic cancer cells by inducing G0/G1 cell cycle arrest. Pharmacology. 2019; 103: 250-6.

[31] Ishii K, Sasaki T, Iguchi K, Kato M, Kanda H, Hirokawa Y, et al. Pirfenidone, an anti-fibrotic drug, suppresses the growth of human prostate cancer cells by inducing G1 cell cycle arrest. J Clin Med. 2019; 4: 8.

[32] Kurimoto R, Ebata T, Iwasawa S, Ishiwata T, Tada Y, Tatsumi K, et al. Pirfenidone may revert the epithelial-to-mesenchymal transition in human lung adenocarcinoma. Oncol Lett. 2017; 14: 944-50.

[33] Yan L, Cao R, Wang L, Liu Y, Pan B, Yin Y, et al. Epithelial-mesenchymal transition in keloid tissues and TGF-β1-induced hair follicle outer root sheath keratinocytes. Wound Repair Regen. 2015; 23: 601-10.

[34] Hahn JM, Glaser K, McFarland KL, Aronow BJ, Boyce ST, Supp DM. Keloid-derived keratinocytes exhibit an abnormal gene expression profile consistent with a distinct causal role in keloid pathology. Wound Repair Regen. 2013; 21: 530-44.

[35] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)). Methods. 2001; 25: 402-8.

[36] Chen J, Liu K, Liu Y, Wang X, Zhang Z. Targeting mTORC1/2 with OSI-027 inhibits proliferation and migration of keloid keratinocytes. Exp Dermatol. 2019; 28: 270-5.

[37] Groger CJ, Grubinger M, Waldhor T, Vierlinger K, Mikulits W. Meta-analysis of gene expression signatures defining the epithelial to mesenchymal transition during cancer progression. PLoS One. 2012; 7: e51136.

[38] Ong CT, Khoo YT, Tan EK, Mukhopadhyay A, Do DV, Han HC, et al. Epithelial-mesenchymal interactions in keloid pathogenesis modulate vascular endothelial growth factor expression and secretion. J Pathol. 2007; 211: 95-108.

[39] Phan TT, Lim IJ, Bay BH, Qi R, Huynh HT, Lee ST, et al. Differences in collagen production between normal and keloid-derived fibroblasts in serum-media co-culture with keloid-derived keratinocytes. J Dermatol Sci. 2002; 29: 26-34.

[40] Fujiwara A, Shintani Y, Funaki S, Kawamura T, Kimura T, Minami M, et al. Pirfenidone plays a biphasic role in inhibition of epithelial-mesenchymal transition in non-small cell lung cancer. Lung Cancer. 2017; 106: 8-16.

[41] Sato M, Shames DS, Hasegawa Y. Emerging evidence of epithelial-to-mesenchymal transition in lung carcinogenesis. Respirology. 2012; 17: 1048-59.

[42] Schafer M, Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol. 2008; 9: 628-38.

[43] Yan L, Cao R, Liu Y, Wang L, Pan B, Lv X, et al. MiR-21-5p links epithelial-mesenchymal transition phenotype with stem-like cell signatures via AKT signaling in keloid keratinocytes. Sci Rep. 2016; 6: 28281.

[44] Zhang M, Liu S, Guan E, Liu H, Dong X, Hao Y, et al. Hyperbaric oxygen therapy can ameliorate the EMT phenomenon in keloid tissue. Medicine. 2018; 97: e11529.

[45] Lei R, Zhang S, Wang Y, Dai S, Sun J, Zhu C. Metformin inhibits epithelial-to-mesenchymal transition of keloid fibroblasts via the HIF-1α/PKM2 signaling pathway. Int J Med Sci. 2019; 16: 960-6.

[46] Supp DM, Hahn JM, McFarland KL, Glaser K. Inhibition of hyaluronan synthase 2 reduces the abnormal migration rate of keloid keratinocytes. J Burn Care Res. 2014; 35: 84-92.

[47] Kodama H, Kumai Y, Nishimoto K, Toya Y, Miyamaru S, Furushima S, et al. Potential treatment for vocal fold scar with pirfenidone. Laryngoscope. 2018; 128: E171-7.

[48] Igota S, Tosa M, Murakami M, Egawa S, Shimizu H, Hyakusoku H, et al. Identification and characterization of Wnt signaling pathway in keloid pathogenesis. Int J Med Sci. 2013; 10: 344-54.

[49] Wang B, Tang Z, Gong H, Zhu L, Liu X. Wnt5a promotes epithelial-to-mesenchymal transition and metastasis in non-small-cell lung cancer. Biosci Rep. 2017; 37.